Fabien Dépis, Ph.D., et. al. Preclinical evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells. Presented at AACR Virtual Annual Meeting, June 22, 2020.
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
(857) 259-3843 firstname.lastname@example.org